| Datum | Källa | Rubrik | Typ | Alternativ |
|---|---|---|---|---|
| 2024-06-14 | Biosergen | Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-06-12 | Biosergen | Biosergen AB: Biosergen to welcome two new board members based on election at the Annual General Meeting | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-06-11 | Carlsquare | Carlsquare: Final permission received, BSG005 to reach patients | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-06-11 | Biosergen | Biosergen AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-06-11 | Biosergen | Biosergen AB: BioStock: Biosergen på väg mot första patientstudien med svampdödande behandling | Pressreleaser | Visa Stäng |
|
Pressreleaser |
Biosergen AB: BioStock: Biosergen på väg mot första patientstudien med svampdödande behandlingLäs hela artikeln på biostock.se: |
||||
| 2024-06-11 | Biosergen | Biosergen AB: BioStock: Biosergen towards first-in-patient trial with antifungal therapy | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-05-31 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2024 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-17 | Biosergen | Notice of annual general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-05-14 | Biosergen | Biosergen AB: BioStock: Biosergens vd "det är ett globalt hälsohot som kräver handling" | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-05-14 | Biosergen | Biosergen AB: BioStock: Biosergen's CEO - "this is a global health threat and it needs attention" | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-05-10 | Biosergen | Biosergen AB: Biosergen publishes 2023 annual report | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-16 | Biosergen | Biosergen AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-04-09 | Biosergen | Biosergen AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-26 | Biosergen | Biosergen AB: Biosergen announces the outcome in the rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-18 | Biosergen | Biosergen AB: BioStock Investor Pitch: Biosergen | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-18 | Biosergen | Biosergen AB: BioStock Investor Pitch: Biosergen | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-15 | Biosergen | Biosergen AB: Members of the board of directors and management subscribe in ongoing rights issue | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-13 | Carlsquare | Carlsquare: Research update Biosergen: Rights issue to fund crucial step for lead project | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-12 | Biosergen | Biosergen AB: BioStock: Emission ska ta Biosergen till första effektdata i människa | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-12 | Biosergen | Biosergen AB: BioStock: Rights issue to give Biosergen first in-human efficacy data | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-08 | Biosergen | Biosergen AB: BioStock: Biosergen angriper osynliga hotet från svampinfektioner | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-08 | Biosergen | Biosergen AB: BioStock: Biosergen attacks invisible threat of fungal infections | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-07 | Carlsquare | Carlsquare: Carlsquare Equity Research interview with Biosergen | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-07 | Biosergen | Biosergen AB: Biosergens vd till BioStock: "Positiva data ger oss starkt erbjudande" | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-07 | Biosergen | Biosergen AB: Biosergen CEO to BioStock: "Positive data give us a strong value proposition" | Pressreleaser | Visa Stäng |
|
|
||||
| 2024-03-05 | Biosergen | Biosergen AB: Biosergen publishes prospectus due to rights issue of units | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-03-01 | Biosergen | Bulletin from the extraordinary general meeting in Biosergen AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-29 | Biosergen | Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-12 | Biosergen | Biosergen AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-02-02 | Carlsquare | Carlsquare: Mrkt BUZZ, Biosergen: Rights issue to fund the next clinical step | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-01-30 | Biosergen | Notice of Extraordinary general meeting in Biosergen AB | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-01-30 | Biosergen | Biosergen AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-01-16 | Carlsquare | Carlsquare: Research Update Biosergen: Licensing deal with Alkem and CTA submission | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-01-12 | Biosergen | Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2024-01-12 | Biosergen | Biosergen AB: Biosergen - Indian collaboration gives boost - Mangold Insight Analys | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-12 | Biosergen | Biosergen AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-12-11 | Carlsquare | Carlsquare: Biosergen, Carlsquare Nordic life science investor day | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Biosergen | Biosergen AB: Biosergen publishes interim report for third quarter 2023 | Rapporter | Ladda ner | Visa Stäng |
|
|
||||
| 2023-11-30 | Biosergen | Biosergen AB changes Certified Adviser to Carnegie Investment Bank AB (publ) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-10-23 | Biosergen | Biosergen AB: Abstract presented at the 11th Trends in Medical Mycology publicly available | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-09-25 | Biosergen | Biosergen AB: Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-28 | Biosergen | Warrants series TO2 were exercised to approximately 96.1 percent and Biosergen AB receives approximately SEK 5.5 million | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-22 | Biosergen | The last day of trading in warrants series TO2 in Biosergen AB is today, August 22, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-16 | Carlsquare | Carlsquare: Research Update Biosergen, Q2 2023: Stable in costs but delays in clinical timeline | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-16 | Biosergen | Biosergen AB: Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-14 | Biosergen | Biosergen AB: Biosergen publishes interim report for first quarter 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-11 | Biosergen | Biosergen AB: The subscription price for warrants series TO2 in Biosergen has been determined to SEK 0.66 and the exercise period starts on August 14, 2023 | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-11 | Biosergen | Biosergen AB: Biosergen publish financial report for second quarter ahead of schedule. | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||
| 2023-08-07 | Biosergen | Biosergen AB: Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11) | Pressreleaser | Ladda ner | Visa Stäng |
|
|
||||